SenesTech, Inc. (SNES) is an American biotechnology company that is leading the way in a modern mutation of pest control. Established in 2004 and headquartered in Flagstaff, Arizona, SenesTech is renowned for its unique and groundbreaking approach to managing rodent populations, primarily through fertility control. The company’s mission is to provide an effective, responsible, and globally acceptable solution for managing pests. They do this by focusing on the introduction and development of non-lethal pest management solutions.
The company’s foremost solution is ContraPest, a product that aims to lower rat populations through fertility control rather than the lethal methods typically used in pest control. Created with an innovative mix of active ingredients, ContraPest targets the reproductive capabilities of both male and female rats, reducing the rate at which populations grow. Uniquely, the bait is designed to be highly palatable, achieving high uptake in rat communities for maximum effectiveness.
Since the primary pest issue worldwide is rats, SenesTech’s alternative approach is having a significant impact. The firm is providing an innovative solution to a global problem by using an environmentally sensitive method to control populations. Their emphasis on non-lethal management represents a paradigm shift in pest control, an industry traditionally dominated by kill methods.
SenesTech’s commitment to sustainable and humane strategies extends to their research methodology, which employs a scientific approach aimed at understanding the complexities of rat reproduction and population dynamics. This commitment to innovation and ethical practice has secured SenesTech’s recognition across industries.
SenesTech, Inc. is listed publicly on the NASDAQ exchange under the trading symbol SNES. Despite the various challenges common in the biotech industry, such as regulatory hurdles and market acceptance, the firm has shown resilience and commitment to its mission.
With an expanding footprint of its flagship product, ContraPest, and an ongoing dedication to further research and development, the company is set to continue its growth in the coming years. In a world increasingly looking for humane and sustainable solutions to age-old problems, SenesTech, Inc. is a pioneering and important player.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
In this CEO Chat, Michael Edell, President and CEO of SenesTech (NASDAQ: SNES), discusses the company's unique approach to rodent control through birth control solutions, emphasizing that they are the only company in this niche. He highlights the transformation of their business model, focusing on in-house e-commerce growth (B2C) and expanding into various B2B verticals, while also introducing strategic assessment services to quantify rodent infestations. Edell addresses the recent underperformance of the stock, attributing it to the early stages of their strategy execution and expressing confidence that the stock price will eventually reflect the company's growth.
SenesTech Inc's CEO, Michael Edell, recently purchased 1,000 shares, increasing his direct ownership to 6,000 shares. This transaction highlights a pattern of strong insider buying at SNES, with 17 buys and only 2 sells over the past year, indicating insider confidence. However, GuruFocus's GF Value suggests the stock is "Significantly Overvalued" at $1.21 per share compared to its intrinsic value of $0.44, presenting a mixed signal for investors.